|Budget Amount *help
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2014: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2012: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|Outline of Final Research Achievements
We tried to define novel autoantibody markers for ACPA negative RA patients using the ProtoArray human protein microarray and ProtoPlex. Candidates were as follows: pogo transposable element with ZNF domain (POGZ), transcript variant 3, Aryl hydrocarbon receptor nuclear translocator, TIMELESS interacting protein (TIPIN), serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), interferon regulatory factor 3 (IRF3), protein kinase C and casein kinase substrate in neurons 1 (PACSIN1), toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP), transcript variant 1, RUN and FYVE domain containing 3 (RUFY3), TBC1 domain family member 22B, hypothetical protein MGC13057 (MGC13057), transcript variant 4, chromosome 16 open reading frame 53 (C16orf53), solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 (SLC9A3R1), MRG-binding protein, tec protein tyrosine kinase (TEC), KIAA0513 (KIAA0513).